Sigma Planning’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VKTX
Sigma Planning's VKTX Position: Q3 2026 in Review
Sigma Planning reduced its Viking Therapeutics (VKTX) stake by 0.32% in Q3 2026, selling an estimated $1.46K and leaving 13,179 shares worth $430K. The position accounts for 0.01% of the portfolio, ranked #911.
Sigma Planning first reported a position in VKTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $957K in Q3 2024. 322 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.
- Sigma Planning held 13,179 shares of Viking Therapeutics worth $430K as of Q3 2026.
- Sigma Planning sold 42 Viking Therapeutics shares in Q3 2026, an estimated $1.46K.
- Viking Therapeutics made up 0.01% of Sigma Planning's portfolio in Q3 2026, its #911 holding.
- Sigma Planning first reported a position in Viking Therapeutics in Q3 2024 and has held it in 5 quarters since.
- Sigma Planning's Viking Therapeutics position peaked at $957K in Q3 2024.
- 322 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.